You just read:

Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST

News provided by

Blueprint Medicines

Jun 14, 2019, 08:45 ET